<SEC-DOCUMENT>0001193125-24-259299.txt : 20241115
<SEC-HEADER>0001193125-24-259299.hdr.sgml : 20241115
<ACCEPTANCE-DATETIME>20241115060527
ACCESSION NUMBER:		0001193125-24-259299
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241114
FILED AS OF DATE:		20241115
DATE AS OF CHANGE:		20241115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241465741

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d903317d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as November 14, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d903317dex991.htm">Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November 14, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d903317dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g903317dsp3.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>at CTOS 2024 Annual Meeting </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant
setting in patients with soft tissue sarcoma </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Over three-fold increase in tumour hyalinization, the primary endpoint of the study and an important predictor of
overall survival, as compared to historical results from radiotherapy alone </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 14</B><B></B><B>&nbsp;November
</B><B>2024 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer
and autoimmune disease, today announces the presentation of new data from <FONT STYLE="white-space:nowrap">EFTISARC-NEO,</FONT> a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy plus KEYTRUDA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) for patients with soft tissue sarcoma (STS), at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting. Based on preliminary analysis among 21 patients available for
primary endpoint assessment, the triple combination therapy demonstrates significant efficacy in the neoadjuvant setting for resectable STS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Katarzyna
Kozak, M.D., Ph.D., and Pawe&#322; Sobczuk, M.D., Ph.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma at MSCNRIO (Warsaw) and the trial&#146;s principal investigators, stated: &#147;Our belief in efti&#146;s unique
mechanism of action to complement radiotherapy and pembrolizumab in order drive better outcomes for patients with this rare aggressive disease was the foundation of the <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> trial. These very
encouraging results we are presenting today build our confidence in the synergistic effects of this new therapeutic approach and its potential to treat these patients in dire need of more effective therapies. In particular, the high level of
hyalinization/fibrosis achieved with this novel combination therapy, three-times above historical results from standard radiotherapy, demonstrates remarkable efficacy in patients with resectable soft tissue sarcomas.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the neoadjuvant setting for patients with resectable STS, the combination achieved a greater than three-fold increase in tumour hyalinization/fibrosis
(median 50%) at the time of surgical resection as compared to a historical median 15% from standard radiotherapy alone. In addition to being the primary endpoint of the <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> study, the tumour
hyalinization/fibrosis rate has also been identified as an important predictor of overall survival for STS patients.<SUP STYLE="font-size:75%; vertical-align:top">1,2</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> trial, with a data <FONT STYLE="white-space:nowrap">cut-off</FONT> of 20&nbsp;October 2024, also
showed 71.4% of patients achieved a pathologic response defined as &#8805;35% of hyalinization/fibrosis and 9.5% of patients achieved a complete pathologic response. The triple combination therapy is safe with no grade &#8805;3 toxicities related to
efti and pembrolizumab. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Fr&eacute;d&eacute;ric Triebel, CSO of Immutep, said: &#147;We are pleased with the strength of these preliminary
results in this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> cancer. To see 71.4% of soft tissue sarcoma patients achieving a pathologic response defined as &#8805;35% of hyalinization/fibrosis
combined with low viable tumour cells at 8% is very promising, especially as strong efficacy has been observed in different STS subtypes. We look forward to further evaluation of efti&#146;s potential as neoadjuvant immunotherapy to help drive
improved clinical outcomes.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g903317dsp3.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ongoing open-label <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> Phase II study, conducted by the
Maria Sk&#322;odowska-Curie National Research Institute of Oncology (MSCNRIO) in Warsaw, is expected to reach the planned enrolment of 40 patients in Q1 CY2025. The trial is primarily funded with an approved grant from the Polish government awarded
by the Polish Medical Research Agency program. For more information, visit clinicaltrials.gov (NCT06128863). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CTOS poster is available on the
Posters&nbsp;&amp; Publications section of Immutep&#146;s website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information,
please visit <U>www.immutep.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Sodali&nbsp;&amp; Co </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>catherine.strong@sodali.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Schaefer IM, Hornick JL, Barysauskas CM, Raut CP, Patel SA, Royce TJ, Fletcher CDM, Baldini EH. Histologic
Appearance After Preoperative Radiation Therapy for Soft Tissue Sarcoma: Assessment of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Response Score. Int J Radiat Oncol Biol Phys. 2017 Jun <FONT
STYLE="white-space:nowrap">1;98(2):375-383.</FONT> doi: 10.1016/j.ijrobp.2017.02.087. Epub 2017 Feb 24. PMID: 28463157. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Rao SR, Lazarides AL, Leckey BL, Lane WO, Visgauss JD, Somarelli JA, Kirsch DG, Larrier NA, Brigman BE,
Blazer DG, Cardona DM, Eward WC. Extent of tumor fibrosis/hyalinization and infarction following neoadjuvant radiation therapy is associated with improved survival in patients with soft-tissue sarcoma. Cancer Med. 2022
<FONT STYLE="white-space:nowrap">Jan;11(1):194-206.</FONT> doi: 10.1002/cam4.4428. Epub 2021 Nov 27. PMID: 34837341; PMCID: PMC8704179. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g903317dsp3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g903317dsp3.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MYX_*@#UR@ H * *5]I-EJ3(;N 2% 0N21C/TJ7%/<B5.,_B1*+*W6Q^Q"/\
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M6>&&Q0-< R2%7VA3(1M8X].H'2@!B:C)'H?VEVW2.Q6+(^8Y;"[@.X[@>AH
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"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
